Molecular Pharmacology is trading at 1.0E-4 as of the 28th of November 2024. This is a No Change since the beginning of the trading day. The stock's open price was 1.0E-4. Molecular Pharmacology has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Molecular Pharmacology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Molecular Pharmacology Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. Molecular Pharmacology Limited is a subsidiary of PharmaNet Group Limited. The company has 111.55 M outstanding shares. More on Molecular Pharmacology
Molecular Pharmacology [MLPH] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Nano-Cap' category with a current market capitalization of 26.77 K. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Molecular Pharmacology's market, we take the total number of its shares issued and multiply it by Molecular Pharmacology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Molecular Pharmacology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 111.55 M outstanding shares.
Molecular Pharmacology currently holds about 1.52 K in cash with (105.41 K) of positive cash flow from operations.
Check Molecular Pharmacology Probability Of Bankruptcy
Our tools can tell you how much better you can do entering a position in Molecular Pharmacology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Premium Stories Now
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Other Information on Investing in Molecular Pink Sheet
Molecular Pharmacology financial ratios help investors to determine whether Molecular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecular with respect to the benefits of owning Molecular Pharmacology security.